Potassium channels as therapeutic targets for autoimmune disorders

Heike Wulff, Christine Beeton, K. George Chandy

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)640-647
Number of pages8
JournalCurrent Opinion in Drug Discovery and Development
Volume6
Issue number5
StatePublished - Sep 2003

Fingerprint

Potassium Channels
T-Lymphocytes
Therapeutics
Immunotherapy
Autoimmune Diseases
Pharmacology

Keywords

  • Effector memory T-cells
  • IKCa1
  • Immunosuppression
  • Kv1.3
  • Multiple sclerosis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Potassium channels as therapeutic targets for autoimmune disorders. / Wulff, Heike; Beeton, Christine; Chandy, K. George.

In: Current Opinion in Drug Discovery and Development, Vol. 6, No. 5, 09.2003, p. 640-647.

Research output: Contribution to journalArticle

Wulff, Heike ; Beeton, Christine ; Chandy, K. George. / Potassium channels as therapeutic targets for autoimmune disorders. In: Current Opinion in Drug Discovery and Development. 2003 ; Vol. 6, No. 5. pp. 640-647.
@article{1688b7e63d7848e2a82085a924d809e3,
title = "Potassium channels as therapeutic targets for autoimmune disorders",
abstract = "In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in na{\"i}ve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.",
keywords = "Effector memory T-cells, IKCa1, Immunosuppression, Kv1.3, Multiple sclerosis",
author = "Heike Wulff and Christine Beeton and Chandy, {K. George}",
year = "2003",
month = "9",
language = "English (US)",
volume = "6",
pages = "640--647",
journal = "Current Opinion in Drug Discovery and Development",
issn = "1367-6733",
publisher = "Current Drugs Ltd.",
number = "5",

}

TY - JOUR

T1 - Potassium channels as therapeutic targets for autoimmune disorders

AU - Wulff, Heike

AU - Beeton, Christine

AU - Chandy, K. George

PY - 2003/9

Y1 - 2003/9

N2 - In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.

AB - In human T-lymphocytes, the voltage-gated Kv1.3 channel and the Ca 2+-activated IKCa1 channel play an important role in Ca2+ signaling, activation, adhesion and migration and have, therefore, long been regarded as attractive targets for immunotherapy. Here, we review the pharmacology of the two channels, their expression pattern in naïve and memory T-cells and their functional roles during T-cell activation, and explain the rationale for the use of Kv1.3 blockers for the therapy of T-cell mediated autoimmune diseases.

KW - Effector memory T-cells

KW - IKCa1

KW - Immunosuppression

KW - Kv1.3

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=0142059887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142059887&partnerID=8YFLogxK

M3 - Article

C2 - 14579513

AN - SCOPUS:0142059887

VL - 6

SP - 640

EP - 647

JO - Current Opinion in Drug Discovery and Development

JF - Current Opinion in Drug Discovery and Development

SN - 1367-6733

IS - 5

ER -